Report cover image

Influenza Medication Market by Drug Class (Baloxavir, Oseltamivir, Peramivir), Delivery Form (Inhalers, Intravenous, Liquid/Syrup), Influenza Type, Distribution Channel, End-User - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 181 Pages
SKU # IRE18444991

Description

Influenza Medication Market by Drug Class (Baloxavir, Oseltamivir, Peramivir), Delivery Form (Inhalers, Intravenous, Liquid/Syrup), Influenza Type, Distribution Channel, End-User - Global Forecast 2024-2030


The Influenza Medication Market size was estimated at USD 3.44 billion in 2023 and expected to reach USD 3.60 billion in 2024, at a CAGR 5.00% to reach USD 4.84 billion by 2030.

Global Influenza Medication Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Influenza Medication Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Influenza Medication Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Influenza Medication Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., AstraZeneca PLC, Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Cocrystal Pharma, Inc., CSL Limited, Daiichi Sankyo Company, Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Lupin Limited, Merck & Co., Inc., NATCO Pharma Limited, Novartis AG, Pfizer Inc., Qiagen N.V., Sandoz International GmbH, Sanofi SA, Shionogi & Co., Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Influenza Medication Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Class
Baloxavir

Oseltamivir

Peramivir

Zanamivir

Delivery Form
Inhalers

Intravenous

Liquid/Syrup

Tablets/Capsules

Influenza Type
Type A

Type B

Type C

Type D

Distribution Channel
Offline

Online

End-User
Ambulatory Surgical Centers

Homecare Facilities

Hospitals & Clinics

Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas

Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam

Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Influenza Medication Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Influenza Medication Market?
3. What are the technology trends and regulatory frameworks in the Influenza Medication Market?
4. What is the market share of the leading vendors in the Influenza Medication Market?
5. Which modes and strategic moves are suitable for entering the Influenza Medication Market?

Note: PDF & Excel + Online Access - 1 Year

Table of Contents

181 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Influenza Medication Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of influenza across the globe
5.1.1.2. Government initiatives and awareness programs for influenza management
5.1.1.3. Growing inclination towards personalized medicine approaches
5.1.2. Restraints
5.1.2.1. Associated high cost of novel influenza drug development
5.1.3. Opportunities
5.1.3.1. Surge in influenza drug approvals from regulatory authorities
5.1.3.2. Favorable investments for development of new formulations and delivery methods
5.1.4. Challenges
5.1.4.1. Adverse health outcomes of influenza medications
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Influenza Medication Market, by Drug Class
6.1. Introduction
6.2. Baloxavir
6.3. Oseltamivir
6.4. Peramivir
6.5. Zanamivir
7. Influenza Medication Market, by Delivery Form
7.1. Introduction
7.2. Inhalers
7.3. Intravenous
7.4. Liquid/Syrup
7.5. Tablets/Capsules
8. Influenza Medication Market, by Influenza Type
8.1. Introduction
8.2. Type A
8.3. Type B
8.4. Type C
8.5. Type D
9. Influenza Medication Market, by Distribution Channel
9.1. Introduction
9.2. Offline
9.3. Online
10. Influenza Medication Market, by End-User
10.1. Introduction
10.2. Ambulatory Surgical Centers
10.3. Homecare Facilities
10.4. Hospitals & Clinics
11. Americas Influenza Medication Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Influenza Medication Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.
10. South Korea
12.
11. Taiwan
12.
12. Thailand
12.
13. Vietnam
13. Europe, Middle East & Africa Influenza Medication Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.
10. Nigeria
13.
11. Norway
13.
12. Poland
13.
13. Qatar
13.
14. Russia
13.
15. Saudi Arabia
13.
16. South Africa
13.
17. Spain
13.
18. Sweden
13.
19. Switzerland
13.
20. Turkey
13.
21. United Arab Emirates
13.
22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. Abbott Laboratories
15.1.2. Agilent Technologies, Inc.
15.1.3. AstraZeneca PLC
15.1.4. Bio-Rad Laboratories, Inc.
15.1.5. Bristol-Myers Squibb Company
15.1.6. Cocrystal Pharma, Inc.
15.1.7. CSL Limited
15.1.8. Daiichi Sankyo Company, Limited
15.1.9. Eli Lilly and Company
15.1.
10. F. Hoffmann-La Roche AG
15.1.
11. GlaxoSmithKline PLC
15.1.
12. Lupin Limited
15.1.
13. Merck & Co., Inc.
15.1.
14. NATCO Pharma Limited
15.1.
15. Novartis AG
15.1.
16. Pfizer Inc.
15.1.
17. Qiagen N.V.
15.1.
18. Sandoz International GmbH
15.1.
19. Sanofi SA
15.1.
20. Shionogi & Co., Ltd.
15.1.
21. Sun Pharmaceutical Industries Ltd.
15.1.
22. Takeda Pharmaceutical Company Limited
15.1.
23. Teva Pharmaceutical Industries Ltd.
15.1.
24. Viatris Inc.
15.1.
25. Zydus Pharmaceuticals, Inc.
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing
FIGURE 1. INFLUENZA MEDICATION MARKET RESEARCH PROCESS
FIGURE 2. INFLUENZA MEDICATION MARKET SIZE, 2023 VS 2030
FIGURE 3. INFLUENZA MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. INFLUENZA MEDICATION MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. INFLUENZA MEDICATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. INFLUENZA MEDICATION MARKET DYNAMICS
FIGURE 7. INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 8. INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2023 VS 2030 (%)
FIGURE 10. INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2023 VS 2030 (%)
FIGURE 12. INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 14. INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 16. INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. INFLUENZA MEDICATION MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 26. INFLUENZA MEDICATION MARKET SHARE, BY KEY PLAYER, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us